MiNK Therapeutics (NASDAQ:INKT) Upgraded by Zacks Research to Strong-Buy Rating
by Tristan Rich · The Markets DailyZacks Research upgraded shares of MiNK Therapeutics (NASDAQ:INKT – Free Report) from a hold rating to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.
A number of other research firms also recently issued reports on INKT. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a research report on Monday, May 18th. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $35.00.
Check Out Our Latest Stock Report on INKT
MiNK Therapeutics Stock Performance
Shares of INKT stock opened at $11.09 on Tuesday. MiNK Therapeutics has a fifty-two week low of $8.48 and a fifty-two week high of $30.64. The stock has a 50 day simple moving average of $11.50 and a two-hundred day simple moving average of $11.39. The company has a market cap of $55.25 million, a P/E ratio of -3.90 and a beta of 0.47.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. On average, research analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current year.
Institutional Trading of MiNK Therapeutics
A hedge fund recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC boosted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.87% of the company’s stock.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.